A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn's Disease

Keshav, S., Vanasek, T., Niv, Y., Petryka, R., Howaldt, S., Bafutto, M., Racz, I., Hetzel, D., Nielsen, O. H., Vermeire, S., Reinisch, W., Karlen, P., Schreiber, Stefan, Schall, T. J. and Bekker, P. (2013) A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn's Disease PLoS ONE, 8 (3).

Full text not available from this repository.

Document Type: Article
Additional Information: Times Cited: 8 Keshav, Satish Vanasek, Tomas Niv, Yaron Petryka, Robert Howaldt, Stephanie Bafutto, Mauro Racz, Istvan Hetzel, David Nielsen, Ole Haagen Vermeire, Severine Reinisch, Walter Karlen, Per Schreiber, Stefan Schall, Thomas J. Bekker, Pirow
Research affiliation: Kiel University
OceanRep > The Future Ocean - Cluster of Excellence
ISSN: 1932-6203
Projects: Future Ocean
Date Deposited: 08 Jul 2014 09:27
Last Modified: 08 Jul 2014 09:27
URI: http://eprints.uni-kiel.de/id/eprint/25027

Actions (login required)

View Item View Item